NHS access: Access to weight loss injections UK-wide follows NICE criteria and local pathways
The multidistrict litigation (MDL) against pharmaceutical giants Novo Nordisk and Eli Lilly, involving GLP-1 drugs such as Ozempic, Wegovy, Trulicity, and Mounjaro, continues to progress as plaintiffs claim these medications have caused serious gastrointestinal injuries
Cost-effective generics and localized distribution strategies improve accessibility, although limited reimbursement coverage remains a barrier
For instance, in May 2025, according to the WHO, 1 in 8 people globally were living with obesity, with 2.5 billion adults overweight, including 890 million with obesity
10.41) + shipping + taxes tati1974 5.0 285 Reviews 1.2K Sold Product Details GLP-1 Metabolic Balance Patches 60 Count (2-Month Pack) Sealed pack of GLP-1 Metabolic Balance Patches by Nrqwmy